AN2 Therapeutics
ANTX
Market cap $30.7M

1.03 USD

-0.03

2.83%

At close Oct 17, 4:00 PM EDT

After hours

1.03

+0.00

0.00%

1 day

-2.83%

5 days

0.00%

1 month

-2.83%

3 months

-65.20%

6 months

-58.47%

Year to date

-94.82%

1 year

-92.92%

5 years

-93.31%

About: AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Employees: 36

Healthcare Pharmaceutical Preparations

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

2.41% more ownership

Funds ownership: 63.01% [Q1] → 65.42% (+2.41%) [Q2]

16% less funds holding

Funds holding: 55 [Q1] → 46 (-9) [Q2]

31% less capital invested

Capital invested by funds: $60.9M [Q1] → $41.9M (-$18.9M) [Q2]

60% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 15

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

191%

upside

Avg. target

191%

upside

High target

191%

upside

1 analyst rating

1 positive

100%

0 neutral

0 negative

JMP Securities

Roy Buchanan

19% 1-year accuracy

3 / 16 met price target

191%upside

Market Outperform

Maintained

9 Aug 2024

See Analyst Rankings

Financial journalist opinion

Neutral

Business Wire

17 hours ago

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria. “We are appreciative of the Gates Foun.

Neutral

24/7 Wall Street

3 weeks ago

3 Penny Stocks To Buy With Just $750

Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky.

Neutral

Business Wire

1 month ago

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference. Details of the event is as follows: H.C. Wainwright 26th Annual Global Investment Conference Eric Easom, Co-Founder, Chairman, Pr.

Neutral

Zacks Investment Research

1 month ago

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

Neutral

Business Wire

2 months ago

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the quarter ended June 30, 2024. “We reported results from the EBO-301 Phase 2/3 study in patients with treatment-refractory MAC lung disease last week and over the coming months will further analyze the data to determine next steps in NTM lung.

Negative

InvestorPlace

2 months ago

Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?

AN2 Therapeutics (NASDAQ: ANTX ) stock is taking a beating on Friday after the company provided an update on its EBO-301 Phase 2/3 study. AN2 Therapeutics notes that information comes from the Phase 2 study of epetraborole as an optimized background regimen (OBR) in treatment-refractory MAC lung disease.

Neutral

Business Wire

2 months ago

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today announced topline results from the Phase 2 part of the EBO-301 Phase 2/3 study evaluating epetraborole on top of an optimized background regimen (OBR) in treatment-refractory MAC lung disease. The Phase 2 part of the study met its primary objective of demonstrating the poten.

$AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease$